In Vitro Assessment of Cardiac Risk in Drug Discovery

Learn how an hiPSC-CM model can help provide clear decision-making data for your project team that can avoid costly issues related to QTc and QRS cardiac liabilities in the clinic.
Presentations:
Opportunities to Leverage Non-clinical Data in a Regulatory Integrated QTc Assessment (Derek Leishman, Vice President Translational and Quantitative Toxicology, Eli Lilly and Company).
A Clinically Translatable hIPSC Cardiomyocyte Model to Predict QTc and QRS Cardiac Risk (Steve Jenkinson, Vice President Drug Discovery and Safety, Metrion Biosciences).
Chaired by Eddy Stevens, CSO, Metrion Biosciences.